Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Jun;19(6):679-84.
doi: 10.5588/ijtld.14.0768.

Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance

A K Alame-Emane  1 , P Xu  2 , C Pierre-Audigier  3 , V Cadet-Daniel  4 , X Shen  5 , M Sraouia  6 , J F Djoba Siawaya  7 , H Takiff  8 , Q Gao  2 , B Gicquel  9
Affiliations
Comparative Study

Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance

A K Alame-Emane et al. Int J Tuberc Lung Dis. 2015 Jun.

Abstract

Background: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (TB) constitute a major public health concern.

Objective: To determine the timing of pncA mutations that confer pyrazinamide (PZA) resistance in relation to mutations conferring resistance to isoniazid (INH) and rifampicin (RMP).

Design: Isolates from two major urban centres--Paris (101 strains) and Shanghai (171 strains)--were investigated for the association of pncA mutations with resistance to drugs other than PZA.

Results: The proportion of pncA mutations found in INH-monoresistant strains was not increased.

Conclusion: pncA mutations associated with PZA resistance were found almost exclusively in MDR-TB strains, underlining the importance of determining PZA resistance when treating MDR- or XDR-TB.

PubMed Disclaimer

Comment in

  • No evidence that pyrazinamide resistance is acquired after fluoroquinolone resistance.
    Cobelens F, Gebhard A, van den Hof S. Cobelens F, et al. Int J Tuberc Lung Dis. 2016 Feb;20(2):282. doi: 10.5588/ijtld.15.0628. Int J Tuberc Lung Dis. 2016. PMID: 26792486 No abstract available.
  • In reply.
    Takiff H, Alame-Emane AK, Pierre-Audigier C, Gicquel B. Takiff H, et al. Int J Tuberc Lung Dis. 2016 Feb;20(2):282-3. doi: 10.5588/ijtld.15.0628-2. Int J Tuberc Lung Dis. 2016. PMID: 26792487 No abstract available.

Publication types

MeSH terms

LinkOut - more resources